Our Company

FDA IND Approval for Phase 2 Clinical Trial for Progressive Supranuclear Palsy (US)

Orphan Drug Designation of GV1001 by the MFDS for the treatment of Progressive Supranuclear Palsy (KR)

Completion of Patient Recruitment for Global Phase 2 Clinical Trial for Alzheimer’s Disease (US, EU)

Announcement of Topline Results for Phase 2 Clinical Trial for Progressive Supranuclear Palsy (KR)

IND Approval for Phase 2 Clinical Trial for Progressive Supranuclear Palsy (KR)

EU IND Approval for Phase 2 Clinical Trial for Alzheimer’s Disease (7 European Countries)

Signing of Domestic License Agreement with Samsung Pharm Co., Ltd. for Alzheimer’s Disease Drug Development

Announcement of Phase 3 Clinical Trial Results for Benign Prostatic Hyperplasia (KR)

Approval of IND for Clinical Extension of Phase 2 Clinical Trial for Progressive Supranuclear Palsy (KR)

IND Approval for Phase 3 Clinical Trial for Alzheimer’s Disease (KR)

Initiation of Global Phase 2 Clinical Trial for Alzheimer’s Disease (US)

FDA IND Approval for Phase 2 Clinical Trial for Alzheimer’s Disease (US)

Announcement of Phase 2 Clinical Trial Results for Alzheimer’s Disease (KR)

Announcement of Phase 3 Clinical Trial Results for Pancreatic Cancer (KR)

Announcement of Phase 3 Clinical Trial Results for TeloVac (UK)

Execution of Management Rights Transfer Agreement with Samsung Pharm Co., Ltd. (Inclusion as an Affiliated Company)

Conditional Approval for the Pancreatic Cancer Immuno-Oncology Drug RIAVAX (KR)

Approval of IND for Phase 3 Clinical Trial for Pancreatic Cancer (KR)

Signing of Domestic License Agreement for RIAVAX with Samsung Pharm Co., Ltd.

Announcement of Phase 2 Clinical Trial Results for Benign Prostatic Hyperplasia (KR)

Company Establishment

KOSDAQ Market Listing

Acquisition of GemVax AS

Acquisition of Teloid